Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-02-07 | Pieris (Germany) | € 1 million | grant | Federal Ministry of Education and Research (BMBF) (Germany) | Cancer - Oncology | Grant |
2012-02-01 | Wilex (Germany) | € 9.93 million | private placement | Cancer - Oncology - Inflammatory diseases | Private placement | |
2012-01-30 | Algenics (France) | undisclosed - This grant is part of a €700 000 phase 1 project. | grant | OSEO (France) | Technology - Services | Grant |
2012-01-25 | Targovax (Norway) | 18.5 million NOK (€2.41 million) | financing round | Radium Hospital Research Foundation (Norway) - Birk Venture (Norway) - RO Invest (Norway) - existing owners | Cancer - Oncology | Fundraising |
2012-01-23 | Prosensa (The Netherlands) | €23 Million | equity financing | New Enterprise Associates (USA) Abingworth (UK) Life Sciences Partners (The Netherlands) Gimv (Belgium) Idinvest Partners (France) MedSciences Capital (The Netherlands) |
Rare diseases - Genetic diseases | Fundraising |
2012-01-23 | Eyevensys (France) | €1.6 million | capital increase | InnoBio (France) - nserm Transfert Initiative (France) | Ophtalmological diseases | Fundraising |
2012-01-20 | Pronota (Belgium) | € 3.7 million | series C financing round | LSP (The Netherlands) - Gimv (Belgium) - Biotech Fund Flanders (Belgium) - KBC Private Equity (Belgium) - Johnson & Johnson Development Corporation (USA) - VIB (Belgium) - MP Healthcare (USA) - MedSciences Capital (The Netherlands) a company founder |
Cancer - Oncology - Infectious diseases | Fundraising |
2012-01-18 | Pluristem Therapeutics (Israel) | NIS 9 million (approximately $2.4 million - €1.8 million) | grant | Office of the Chief Scientist (OCS -Israel) | Cardiovascular diseases - Regenerative medicine | Grant |
2012-01-18 | Pherecydes Pharma (France) | €900 000 | grant | DGA - | Infectious diseases | Grant |
2012-01-18 | Oxford Cancer Biomarkers (UK) | undisclosed | private investment | Quintiles (USA) |
||
2012-01-12 | ProteoMediX (Switzerland) | CHF 2.6 million (€2.1 million) | Series A equity financing round | Altos Venture (Switzerland) - BioValley Business Angels Club BioBAC (Switzerland) - Zürcher Kantonalbank (Switzerland) | Cancer - Oncology | Fundraising |
2012-01-12 | Cell Medica (UK) | grant | Technology Strategy Board (UK) | Cancer - Oncology - Infectious diseases | Grant | |
2012-01-10 | Telormedix (Switzerland) | CHF 7.5 Million (€6.1million) | Aravis Venture ( Switzerland) - Proquest Investments (USA) | Cancer - Oncology - Inflammatory diseases | Establishment of a new subsidiary in the EU | |
2012-01-05 | AMP Therapeutics (Germany) | undisclosed | series A financing round | Boehringer Ingelheim Venture Fund (Germany) - Novartis Venture Fund (Switzerland) | Infectious diseases | Fundraising |
2012-01-05 | Midatech (UK) | £6.3 Million (€7.6 million) | private investment | Cancer - Oncology | Private placement | |
2012-01-04 | Probiodrug (Germany) | €15 Million | fundraising | Inflammatory diseases - Neurodegenerative diseases | Fundraising | |
2012-01-04 | BerGenBio (Norway) | $8.8 million (€6.8 million) | Series A financing round | Sarsia Seed AS (Norway) - Investinor AS (Norway) | Cancer - Oncology | Fundraising |
2012-01-04 | Pharmalink (Sweden) | SEK 35 million (€4million) | existing shareholders | Renal diseases | Fundraising | |
2012-01-02 | Galecto Biotech (Sweden) | seed financing | Merck Serono Ventures (Switzerland) - Novo A/S (Denmark) - Forskarpatent (Sweden) | Inflammatory diseases | Fundraising | |
2011-12-30 | Amsterdam Molecular Therapeutics (the Netherlands) | €2.5 million | private placement | Forbion Capital Partners (The Netherlands) - Gilde Healthcare Partners (The Netherlands) - Advent Venture Partners (UK) | Rare diseases - Genetic diseases | Private placement |